Last 765.00 GBp
Change Today +19.00 / 2.55%
Volume 320.0K
BTG On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 9:13 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Fleet Place

London, EC4M 7RD

United Kingdom

Phone: 44 20 7575 0000

Fax: 44 20 7575 0010

BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTG:LN 765.00 GBp +19.00

BTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Richter Gedeon Nyrt 3,839 +69.00
Merit Medical Systems Inc $19.50 USD 0.00
Pfizer Ltd/India 2,078 INR 0.00
RPX Corp $14.29 USD 0.00
Sirtex Medical Ltd A$35.79 AUD +0.89
View Industry Companies
 

Industry Analysis

BTG

Industry Average

Valuation BTG Industry Range
Price/Earnings 63.9x
Price/Sales 7.7x
Price/Book 4.3x
Price/Cash Flow 40.1x
TEV/Sales 8.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.